Avelumab treats Merkel Cell Carcinoma (MCC) through immune checkpoint inhibition, specifically by targeting and blocking the PD-L1 protein on tumor cells. Normally, PD-L1 interacts with the PD-1 receptor on T cells, leading to immune suppression that allows cancer cells to evade immune detection. This evidence concerns the gene CD274 and Merkel cell skin cancer.